Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Blepharitis Therapeutics Pipeline Review 2016 - 6 Companies & Drug Profiles - Research and Markets

Research and Markets
Posted on: 19 Sep 16

Research and Markets has announced the addition of the "Blepharitis - Pipeline Review, H2 2016" drug pipelines to their offering.

'Blepharitis - Pipeline Review, H2 2016'; Blepharitis pipeline therapeutics constitutes close to 8 molecules. Out of which approximately 8 molecules are developed by Companies.

Blepharitis is an inflammation of the eyelids, usually caused by an excess growth of bacteria that is ordinarily found on the skin, blockage of the eyelid's oil glands, and occasionally allergies. Blepharitis signs and symptoms include watery eyes, red eyes, itchy eyelids, sensitivity to light. Treatment includes antibiotics, lubricating eye drops and steroid eye drops or ointments.

'Blepharitis - Pipeline Review, H2 2016' outlays comprehensive information on the therapeutics under development for Blepharitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews of key players involved in therapeutic development for Blepharitis and features dormant and discontinued projects. Currently, The molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 2, 1 and 2 respectively.

Key Topics Covered:

  1. Introduction
  2. Blepharitis Overview
  3. Therapeutics Development
  4. Pipeline Products for Blepharitis - Overview
  5. Pipeline Products for Blepharitis - Comparative Analysis
  6. Blepharitis - Therapeutics under Development by Companies
  7. Blepharitis - Therapeutics under Investigation by Universities/Institutes
  8. Blepharitis Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Blepharitis - Products under Development by Companies
  13. Blepharitis - Products under Investigation by Universities/Institutes
  14. Blepharitis - Companies Involved in Therapeutics Development
  • Allergan Plc
  • InSite Vision Incorporated
  • Kala Pharmaceuticals, Inc.
  • NicOx S.A.
  • Quorum Innovations LLC
  • Senju Pharmaceutical Co., Ltd.

For more information about this drug pipelines report visit

Related Topics: Optical

View source version on

Business Wire

Last updated on: 19/09/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.